Patents by Inventor Minsheng He
Minsheng He has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230416212Abstract: The invention relates to crystalline forms of the bis-HCl salt of a compound represented by Structural Formula 1, and pharmaceutical compositions comprising crystalline forms of the bis-HCL salt of a compound represented by Structural Formula 1 described herein. The crystalline forms of the bis-HCl salt of a compound of Structural Formula 1 and compositions comprising the crystalline forms of the compound of Structural Formula 1 provided herein, in particular, crystalline Form I, crystalline Form J, crystalline Form A, and crystalline Form B, or mixtures thereof, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders. Also described herein are methods for preparing the crystalline forms (e.g., Forms I, J, B and A) of the bis-HCl salt of a compound represented by Structural Formula 1.Type: ApplicationFiled: January 5, 2023Publication date: December 28, 2023Inventors: Danny Lafrance, Philip C. Hogan, Yansheng Liu, Minsheng He, Chi-Li Chen, John Niu
-
Publication number: 20230357180Abstract: Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.Type: ApplicationFiled: December 12, 2022Publication date: November 9, 2023Applicant: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Minsheng He, Kiel Lazarski
-
Patent number: 11753397Abstract: The invention provides cereblon binders of Formulas: or pharmaceutically acceptable salts thereof, for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway along with their use in therapeutic applications to treat medical disorders including, but not limited to cancer.Type: GrantFiled: September 24, 2020Date of Patent: September 12, 2023Assignee: C4 Therapeutics, Inc.Inventors: James A. Henderson, Gesine Kerstin Veits, Minsheng He, Christopher G. Nasveschuk, Andrew J. Phillips, Andrew Charles Good
-
Publication number: 20230279023Abstract: This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.Type: ApplicationFiled: October 3, 2022Publication date: September 7, 2023Applicant: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Martin Duplessis, Chi-Li Chen
-
Publication number: 20230190760Abstract: New treatments for Ikaros and/or Aiolos mediated disorders are provided that comprise administering an effective amount of a cereblon binder that degrades Ikaros or Aiolos by the ubiquitin proteasome pathway.Type: ApplicationFiled: February 7, 2023Publication date: June 22, 2023Applicant: C4 Therapeutics, Inc.Inventors: David Proia, James A. Henderson, Minsheng He, Andrew Charles Good, Andrew J. Phillips
-
Publication number: 20230082430Abstract: Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.Type: ApplicationFiled: April 18, 2022Publication date: March 16, 2023Applicant: C4 Therapeutics, Inc.Inventors: James A. Henderson, Minsheng He, Andrew Charles Good, Andrew John Phillips
-
Patent number: 11578044Abstract: The invention relates to crystalline forms of the bis-HCl salt of a compound represented by Structural Formula 1, and pharmaceutical compositions comprising crystalline forms of the bis-HCL salt of a compound represented by Structural Formula 1 described herein. The crystalline forms of the bis-HCl salt of a compound of Structural Formula 1 and compositions comprising the crystalline forms of the compound of Structural Formula 1 provided herein, in particular, crystalline Form I, crystalline Form J, crystalline Form A, and crystalline Form B, or mixtures thereof, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders. Also described herein are methods for preparing the crystalline forms (e.g., Forms I, J, B and A) of the bis-HCl salt of a compound represented by Structural Formula 1.Type: GrantFiled: March 1, 2021Date of Patent: February 14, 2023Assignee: Tetraphase Pharmaceuticals, Inc.Inventors: Danny LaFrance, Philip C. Hogan, Yansheng Liu, Minsheng He, Chi-Li Chen, John Niu
-
Publication number: 20230014124Abstract: This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.Type: ApplicationFiled: February 1, 2021Publication date: January 19, 2023Applicant: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Mark E. Fitzgerald, Minsheng He, Ryan E. Michael
-
Patent number: 11524949Abstract: Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.Type: GrantFiled: May 14, 2020Date of Patent: December 13, 2022Assignee: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Minsheng He, Kiel Lazarski
-
Publication number: 20220372016Abstract: This invention provides pharmaceutical protein degraders and E3 ubiquitin ligase binders for therapeutic applications as described further herein.Type: ApplicationFiled: June 18, 2021Publication date: November 24, 2022Applicant: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Katrina L. Jackson, Minsheng He, Yanke Liang, Mark E. Fitzgerald, Victoria Garza
-
Publication number: 20220313826Abstract: This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.Type: ApplicationFiled: November 30, 2020Publication date: October 6, 2022Applicant: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Kiel Lazarski, Gesine Kerstin Veits, Harit U. Vora
-
Publication number: 20220313827Abstract: This invention provides amine-linked C3-glutarimide Degronimers and Degrons for therapeutic applications as described further herein, and methods of use and compositions thereof as well as methods for their preparation.Type: ApplicationFiled: December 14, 2020Publication date: October 6, 2022Applicant: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Chris G. Nasveschuk, James A. Henderson, Yanke Liang, Chi-li Chen, Martin Duplessis, Minsheng He, Kiel Lazarski
-
Patent number: 11459335Abstract: This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.Type: GrantFiled: December 19, 2019Date of Patent: October 4, 2022Assignee: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Martin Duplessis, Chi-Li Chen
-
Publication number: 20220251061Abstract: Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.Type: ApplicationFiled: May 14, 2020Publication date: August 11, 2022Applicant: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Minsheng He, Kiel Lazarski
-
Patent number: 11407732Abstract: Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.Type: GrantFiled: October 11, 2021Date of Patent: August 9, 2022Assignee: C4 Therapeutics, Inc.Inventors: James A. Henderson, Minsheng He, Andrew Charles Good, Andrew John Phillips
-
Publication number: 20210395198Abstract: The invention relates to crystalline forms of the bis-HCl salt of a compound represented by Structural Formula (1), and pharmaceutical compositions comprising crystalline forms of the bis-HCL salt of a compound represented by Structural Formula (1) described herein. The crystalline forms of the bis-HCl salt of a compound of Structural Formula (1) and compositions comprising the crystalline forms of the compound of Structural Formula (1) provided herein, in particular, crystalline Form A, crystalline Form B, crystalline Form C, and crystalline Form D, or mixtures thereof, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders. Also described herein are methods for preparing the crystalline forms (e.g., Forms A, B, C and D) of the bis-HCl salt of a compound represented by Structural Formula (1).Type: ApplicationFiled: November 8, 2019Publication date: December 23, 2021Inventors: Wu-Yan Zhang, Minsheng He
-
Publication number: 20210363103Abstract: The invention relates to crystalline forms of the bis-HCl salt of a compound represented by Structural Formula 1, and pharmaceutical compositions comprising crystalline forms of the bis-HCL salt of a compound represented by Structural Formula 1 described herein. The crystalline forms of the bis-HCl salt of a compound of Structural Formula 1 and compositions comprising the crystalline forms of the compound of Structural Formula 1 provided herein, in particular, crystalline Form I, crystalline Form J, crystalline Form A, and crystalline Form B, or mixtures thereof, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders. Also described herein are methods for preparing the crystalline forms (e.g., Forms I, J, B and A) of the bis-HCl salt of a compound represented by Structural Formula 1.Type: ApplicationFiled: March 1, 2021Publication date: November 25, 2021Inventors: Danny Lafrance, Philip C. Hogan, Yansheng Liu, Minsheng He, Chi-Li Chen, John Niu
-
Patent number: 10961190Abstract: The invention relates to crystalline forms of the bis-HCI salt of a compound represented by Structural Formula 1, and pharmaceutical compositions comprising crystalline forms of the bis-HCL salt of a compound represented by Structural Formula 1 described herein. The crystalline forms of the bis-HCl salt of a compound of Structural Formula 1 and compositions comprising the crystalline forms of the compound of Structural Formula 1 provided herein, in particular, crystalline Form I, crystalline Form J, crystalline Form A, and crystalline Form B, or mixtures thereof, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders. Also described herein are methods for preparing the crystalline forms (e.g., Forms I, J, B and A) of the bis-HCI salt of a compound represented by Structural Formula 1.Type: GrantFiled: October 19, 2017Date of Patent: March 30, 2021Assignee: Tetraphase Pharmaceuticals, Inc.Inventors: Danny LaFrance, Philip C. Hogan, Yansheng Liu, Minsheng He, Chi-Li Chen, John Niu
-
Patent number: 10913712Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.Type: GrantFiled: April 24, 2019Date of Patent: February 9, 2021Assignee: Tetraphase Pharmaceuticals, Inc.Inventors: Xiao-Yi Xiao, Roger B. Clark, Diana Katharine Hunt, Cuixiang Sun, Magnus P. Ronn, Wu-Yan Zhang, Minsheng He
-
Patent number: 10905768Abstract: This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.Type: GrantFiled: May 11, 2020Date of Patent: February 2, 2021Assignee: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Chris G. Nasveschuk, James A. Henderson, Yanke Liang, Mark E. Fitzgerald, Minsheng He, Ryan E. Michael